The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| HRTX | -28.18% | -92.09% | -39.8% | -100% |
| S&P | +15.06% | +95.03% | +14.29% | +1,913% |
Heron Therapeutics, Inc is a biotechnology company, which engages in the development of pharmaceutical products for acute care and oncology patients. Its product portfolio includes SUSTOL, CINVANTI, HTX-011 and HTX-034. The company was founded in February 1983 and is headquartered in San Diego, CA.
These two biopharma stocks could be poised for a major growth spurt.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $37.20M | 3.3% |
| Gross Profit | $27.34M | 7.2% |
| Gross Margin | 73.50% | 2.7% |
| Market Cap | $315.81M | -40.1% |
| Market Cap / Employee | $2.59M | 0.0% |
| Employees | 122 | -3.2% |
| Net Income | -$2.38M | 74.2% |
| EBITDA | -$0.83M | 85.8% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $16.52M | -10.2% |
| Accounts Receivable | $79.93M | 8.4% |
| Inventory | 73 | 70.2% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00M | -100.0% |
| Short Term Debt | $176.74M | 5433.6% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -0.41% | 22.5% |
| Return On Invested Capital | -75.97% | 7.9% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$11.08M | -111.3% |
| Operating Free Cash Flow | -$10.87M | -136.1% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | -7.55 | -5.80 | -9.95 | -11.09 | -28.86% |
| Price to Sales | 2.21 | 1.62 | 2.92 | 2.13 | -45.52% |
| Price to Tangible Book Value | -7.55 | -5.80 | -9.95 | -11.09 | -28.86% |
| Enterprise Value to EBITDA | -106.14 | 74.21 | 151.09 | -550.76 | 396.04% |
| Total Debt | $178.25M | $177.76M | $177.26M | $176.74M | -1.10% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
